Research and Markets: Threats to Avastin - Targeting the Vascular Endothelial Growth Factor Pathway

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/918e3b/threats_to_avastin) has announced the addition of the "Threats to Avastin - Targeting the VEGF Pathway" report to their offering.

Avastin is set to become the most successful cancer treatment to date and one of the leading drugs with sales likely to exceed US$9 billion by 2015.

Since its launch in 2004, Avastin has achieved strong growth culminating in sales of US$5,731 million (SFr 6.2 billion) in 2009. Not only is Avastin now Roches top-selling oncology product, ahead of both MabThera/Rituxan (rituximab) and Herceptin (trastuzumab), but its sales exceed those of every other cancer product on the market.

In 2009, solid growth was seen across all markets, driven by continued uptake in colorectal cancer (CRC), breast cancer (BC) and non-small cell lung cancer (NSCLC). In the US, metastatic BC was the main growth driver, helped by launches for the new indications of glioblastoma and renal cell carcinoma (RCC). Strong growth was seen in the EU in all indications. In the Japanese market, Avastin sales growth was particularly strong with continued substantial uptake in CRC, enhanced by its recent approval for NSCLC.

While its first-to-market status and Roches experience in the oncology sector have provided a sound basis for growth, a number of related angiogenesis products have been launched and many more are on the horizon. What threat do they present to Avastins status and when will their impact be felt?

The current market Avastin is the only product that currently directly inhibits VEGF. Competing products take a different approach. Bayer/Onyx Nexavar, Pfizers Sutent and GSKs Votrient/Armala are all multi-kinase inhibitors and Pfizers Torisel and Novartis Afinitor are mTOR (kinase) inhibitors.

Looking forward... Drugs with novel mechanisms of inhibiting angiogenesis are beginning to emerge in company pipelines. Espicom has identified 13 major projects in Phase III development, with a further 10 in Phase II. Novel agents include:

Enzastaurin: A novel agent that acts through inhibition of protein kinase C and has been found to suppress tumour growth through multiple mechanisms, such as the direct suppression of tumour cell proliferation.

Panobinostat: This pan-histone deacetylase inhibitor targets multiple oncogenic pathways, including angiogenesis.

PF-02341066: This is a selective ATP-competitive small-molecule inhibitor of both c-Met/hepatocyte growth factor receptor and anaplastic lymphoma kinase tyrosine kinases and their oncogenic variants.

This new report, published April 2010, evaluates Avastin and puts it into its market and competitive context with in-depth analysis of the products and companies that may shape the competitive landscape in the future.

With this report you will...

  • Understand Avastins unique position in the oncology market
  • Evaluate its strengths and weaknesses relative to other VEGF-targeting products
  • Gain insight into the prevalence of cancers in Avastins therapeutic window
  • Review the merits of 21 late-phase development prospects with the analysts unique 5-point competitive assessment
  • Know the launch timeframe for up and coming products
  • Estimate future revenues with 5-year forecasts for more than 20 launched and late-phase products

Just some of the approaches being used by products in this report

  • VEGFr-1, -2 and -3 tyrosine kinase inhibitors
  • VEGF Trap
  • MET & RET inhibitors
  • PDGFr inhibitors
  • HDAC inhibitors

Questions answered by the report include...

  • Which other products in the pipeline mirror Avastins therapeutic approach?
  • What are the extension indications Avastin is expected to secure to 2016?
  • In 2012, five products targeting the VEGF pathway are expected to launch what are they and who are the developers?
  • Why is Amgen/Takedas motesanib/AMG 706 expected to achieve revenues in excess of US$1 billion by 2014?

For more information visit http://www.researchandmarkets.com/research/918e3b/threats_to_avastin

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.